Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C andHaemophilus influenzaeType b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age

Detection of IgG-class antibodies to measles, mumps, rubella, and varicella-zoster virus using a multiplex bead immunoassay

(2010) Neelam Dhiman et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months

(2010) Javier Díez-Domingo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom

(2010) David Goldblatt et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine

(2009) Julia Stowe et al.   VACCINE

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial

(2008) D Pace et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

(2008) J. Southern et al.   Clinical and Vaccine Immunology